In clinical trials, the drug was shown to almost double the median survival time for patients with pancreatic cancer.
Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...
23don MSN
Pancreatic cancer patient Ben Sasse sees 'massive' tumor reduction with experimental new drug
Former Sen. Ben Sasse of Nebraska reveals an experimental cancer drug helped shrink his tumors by 76% after a stage 4 metastatic pancreatic cancer diagnosis.
Former U.S. Senator Ben Sasse of Nebraska was diagnosed with terminal pancreatic cancer. He says a "miracle drug" caused tumors to shrink, extending his life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results